These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31288584)

  • 1. Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial.
    Di WL; Lwin SM; Petrova A; Bernadis C; Syed F; Farzaneh F; Moulding D; Martinez AE; Sebire NJ; Rampling D; Virasami A; Zamiri M; Wang W; Hara H; Kadiyirire T; Abdul-Wahab A; Martinez-Queipo M; Harper JI; McGrath JA; Thrasher AJ; Mellerio JE; Qasim W
    Hum Gene Ther; 2019 Sep; 30(9):1067-1078. PubMed ID: 31288584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome.
    Di WL; Mellerio JE; Bernadis C; Harper J; Abdul-Wahab A; Ghani S; Chan L; Martinez-Queipo M; Hara H; McNicol AM; Farzaneh F; McGrath J; Thrasher A; Qasim W
    Hum Gene Ther Clin Dev; 2013 Dec; 24(4):182-90. PubMed ID: 24329107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.
    Di WL; Larcher F; Semenova E; Talbot GE; Harper JI; Del Rio M; Thrasher AJ; Qasim W
    Mol Ther; 2011 Feb; 19(2):408-16. PubMed ID: 20877344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
    Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
    J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
    Zingkou E; Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression.
    Di WL; Semenova E; Larcher F; Del Rio M; Harper JI; Thrasher AJ; Qasim W
    Hum Gene Ther; 2012 Jan; 23(1):83-90. PubMed ID: 21895535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proinflammatory role of KLK6 protease in Netherton syndrome.
    Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
    J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel SPINK5 donor splice site variant in a child with Netherton syndrome.
    Mintoff D; Borg I; Vornweg J; Mercieca L; Merdzanic R; Numrich J; Aquilina S; Pace NP; Fischer J
    Mol Genet Genomic Med; 2021 Mar; 9(3):e1611. PubMed ID: 33534181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study protocol for ex-vivo lentiviral gene therapy for the inherited skin disease, Netherton Syndrome.
    Di WL; Mellerio JE; Bernadis C; Harper J; Abdul-Wahab A; Ghani S; Martinez-Queipo M; Hara H; McNicol AM; McGrath J; Thrasher AJ; Qasim W
    Hum Gene Ther Clin Dev; 2013 Oct; ():. PubMed ID: 24138501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netherton Syndrome Caused by Heterozygous Frameshift Mutation Combined with Homozygous c.1258A>G Polymorphism in
    Moltrasio C; Romagnuolo M; Riva D; Colavito D; Ferrucci SM; Marzano AV; Tadini G; Brena M
    Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
    Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
    Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Netherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large-sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin.
    Zhang Z; Pan C; Wei R; Li H; Yang Y; Chen J; Li M; Yao Z
    Mol Genet Genomic Med; 2021 Mar; 9(3):e1600. PubMed ID: 33452875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology.
    Guo JZ; Su J; Dai H; Wang XY; Wu WB; Chen T; Zhang J; Wang WH
    Eur J Dermatol; 2022 Jul; 32(4):459-463. PubMed ID: 36301754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of interleukin-33 in the epidermis of two Japanese patients with Netherton syndrome.
    Konishi T; Tsuda T; Sakaguchi Y; Imai Y; Ito T; Hirota S; Yamanishi K
    J Dermatol; 2014 Mar; 41(3):258-61. PubMed ID: 24506793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
    Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Netherton syndrome previously misdiagnosed as hyper IgE syndrome caused by a probable mutation in SPINK5 C.
    Özyurt K; Atasoy M; Ertaş R; Ulaş Y; Akkuş MR; Kiraz A; Hennies HC
    Turk J Pediatr; 2019; 61(4):604-607. PubMed ID: 31990481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
    Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
    J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
    PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.
    Di WL; Hennekam RC; Callard RE; Harper JI
    Br J Dermatol; 2009 Aug; 161(2):404-12. PubMed ID: 19438860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.